Trends in Atopic Dermatitis-From Standard Pharmacotherapy to Novel Drug Delivery Systems.
atopic dermatitis
drug delivery systems
nanoparticles
nanotechnology
pharmacological treatment
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
12 Nov 2019
12 Nov 2019
Historique:
received:
10
10
2019
revised:
06
11
2019
accepted:
11
11
2019
entrez:
16
11
2019
pubmed:
16
11
2019
medline:
2
4
2020
Statut:
epublish
Résumé
Atopic dermatitis (AD) is a predominant and deteriorating chronic inflammation of the skin, categorized by robust burning and eczematous lacerations in diverse portions of the body. AD affects about 20% of both offspring and adults worldwide. The pathophysiology of AD combines environmental, hereditary, and immunological aspects, together with skin barrier dysfunction. The procedures used to prevent the disease are the everyday usage of creams to support the restoration of the epidermal barrier. The classical treatments include the use of topical corticosteroids as a first-line therapy, but also calcineurin inhibitors, antihistamines, antibiotics, phototherapy, and also immunosuppressant drugs in severe cases of AD. Topical drug delivery to deeper skin layers is a difficult task due to the skin anatomic barrier, which limits deeper penetration of drugs. Groundbreaking drug delivery systems, based on nanoparticles (NPs), have received much attention due to their ability to improve solubility, bioavailability, diffusion, targeting to specific types of cells, and limiting the secondary effects of the drugs employed in the treatment of AD. Even so, additional studies are still required to recognize the toxicological characteristics and long-term safety of NPs. This review discusses the current classical pharmacotherapy of AD against new nanoparticle skin delivery systems and their toxicologic risks.
Identifiants
pubmed: 31726723
pii: ijms20225659
doi: 10.3390/ijms20225659
pmc: PMC6888057
pii:
doi:
Substances chimiques
Anti-Allergic Agents
0
Anti-Inflammatory Agents
0
Immunosuppressive Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Portuguese Science and Technology Foundation (FCT/MCT) and from European Funds (PRODER/COMPETE)
ID : M-ERA-NET/0004/2015-PAIRED and UID/AGR/04033/2019 (CITAB)
Organisme : Institute of Nanoscience and Nanotechnology
ID : project ART(2018)
Références
Nano Rev Exp. 2017 Jun 07;8(1):1325708
pubmed: 30410704
Int J Cosmet Sci. 2008 Jun;30(3):157-65
pubmed: 18452432
FEBS Lett. 2006 Oct 9;580(23):5456-66
pubmed: 16962101
Semin Cutan Med Surg. 2011 Jun;30(2):71-86
pubmed: 21767767
J Biomed Nanotechnol. 2010 Oct;6(5):558-68
pubmed: 21329048
Curr Pharm Des. 2019;25(11):1312-1334
pubmed: 31465282
J Liposome Res. 2014 Sep;24(3):249-57
pubmed: 24646413
Drug Deliv Transl Res. 2019 Apr;9(2):520-533
pubmed: 29488170
Clin Dermatol. 2017 Jul - Aug;35(4):344-348
pubmed: 28709563
Carbohydr Polym. 2018 Oct 1;197:478-489
pubmed: 30007638
An Bras Dermatol. 2014 Jan-Feb;89(1):126-36
pubmed: 24626657
Pharmaceutics. 2019 May 13;11(5):null
pubmed: 31085997
Adv Immunol. 2016;132:91-134
pubmed: 27769509
Polymers (Basel). 2019 Oct 15;11(10):null
pubmed: 31618858
Eur J Pharm Biopharm. 2015 Sep;95(Pt B):261-70
pubmed: 25681744
Pharmaceutics. 2019 Jul 24;11(8):null
pubmed: 31344882
Nanomaterials (Basel). 2019 May 31;9(6):null
pubmed: 31159219
Clin Dermatol. 2018 Sep - Oct;36(5):648-652
pubmed: 30217277
Pediatrics. 2015 Sep;136(3):554-65
pubmed: 26240216
Saudi Pharm J. 2017 Feb;25(2):231-235
pubmed: 28344473
Int J Pharm. 2019 Jan 10;554:105-115
pubmed: 30395953
Colloids Surf B Biointerfaces. 2009 Aug 1;72(1):48-56
pubmed: 19403277
Allergy. 2018 Jun;73(6):1284-1293
pubmed: 29319189
AAPS PharmSciTech. 2013 Dec;14(4):1284-93
pubmed: 23959702
Colloids Surf B Biointerfaces. 2018 Nov 1;171:501-505
pubmed: 30081382
Immunol Rev. 2011 Jul;242(1):233-46
pubmed: 21682749
Int J Pharm. 2018 Jan 15;535(1-2):1-17
pubmed: 29111097
J Invest Dermatol. 2012 Mar;132(3 Pt 2):964-75
pubmed: 22217738
Crit Rev Ther Drug Carrier Syst. 2009;26(6):523-80
pubmed: 20402623
Curr Allergy Asthma Rep. 2014 May;14(5):433
pubmed: 24633617
Clin Dermatol. 2016 Sep-Oct;34(5):607-13
pubmed: 27638440
J Clin Aesthet Dermatol. 2013 Oct;6(10):16-22
pubmed: 24155988
Int J Pharm. 2016 Sep 25;511(2):719-27
pubmed: 27480398
J Eur Acad Dermatol Venereol. 2018 May;32(5):657-682
pubmed: 29676534
Dermatol Ther. 2013 Mar-Apr;26(2):110-9
pubmed: 23551368
Immunol Med. 2019 Mar;42(1):10-15
pubmed: 31204894
Angew Chem Int Ed Engl. 2019 Mar 4;58(10):2958-2978
pubmed: 29926520
J Adv Pharm Technol Res. 2010 Jul;1(3):274-82
pubmed: 22247858
Clin Cosmet Investig Dermatol. 2015 Oct 05;8:511-20
pubmed: 26491366
Curr Pharm Des. 2015;21(20):2784-800
pubmed: 25925118
Colloids Surf B Biointerfaces. 2015 May 1;129:191-7
pubmed: 25863712
Colloids Surf B Biointerfaces. 2015 Jun 1;130:40-7
pubmed: 25899842
Molecules. 2018 Dec 19;23(12):null
pubmed: 30572626
Vet J. 2016 Jun;212:58-64
pubmed: 27256026
Drug Discov Today. 2016 May;21(5):789-801
pubmed: 26780385
Adv Exp Med Biol. 2017;1027:11-19
pubmed: 29063427
Handb Exp Pharmacol. 2013;(216):355-72
pubmed: 23563666
Eur J Pharm Sci. 2017 Aug 30;106:177-184
pubmed: 28576561
Curr Drug Deliv. 2016;13(4):482-93
pubmed: 25707403
Immunol Allergy Clin North Am. 2015 Feb;35(1):161-83
pubmed: 25459583
J Control Release. 2000 Apr 3;65(3):403-18
pubmed: 10699298
Colloids Surf B Biointerfaces. 2018 Jul 1;167:337-344
pubmed: 29684903
Iran Biomed J. 2016;20(1):1-11
pubmed: 26286636
Lancet. 2016 Mar 12;387(10023):1109-1122
pubmed: 26377142
J Pharm Sci. 2013 Mar;102(3):1063-75
pubmed: 23303620
Eur J Pharm Sci. 2014 Oct 15;63:29-35
pubmed: 25010261
ISRN Allergy. 2014 Apr 02;2014:354250
pubmed: 25006501
Br J Dermatol. 2014 Jul;170 Suppl 1:2-6
pubmed: 24720512
J Clin Med. 2015 May 06;4(5):884-917
pubmed: 26239454
Sci Rep. 2017 Jun 21;7(1):3979
pubmed: 28638049
Dev Period Med. 2018;22(4):396-403
pubmed: 30636240
Int J Nanomedicine. 2016 May 25;11:2279-304
pubmed: 27307730
Curr Pharm Biotechnol. 2015;16(4):303-12
pubmed: 25601600
Int J Pharm. 2012 Sep 15;434(1-2):70-9
pubmed: 22609427
Indian J Dermatol. 2016 Nov-Dec;61(6):656-661
pubmed: 27904185
Pediatric Health Med Ther. 2015 Jun 25;6:93-99
pubmed: 29388578
Acta Derm Venereol. 2016 Nov 2;96(7):948-953
pubmed: 26939522
Eur J Immunol. 2017 Jan;47(1):60-67
pubmed: 27748951
Int J Nanomedicine. 2017 Dec 22;13:129-142
pubmed: 29317821
Drug Deliv Transl Res. 2019 Apr;9(2):469-481
pubmed: 29159691
Eur J Pharm Biopharm. 2016 Nov;108:235-252
pubmed: 27519829
Adv Exp Med Biol. 2017;1027:185-210
pubmed: 29063440
Int J Pharm. 2016 Mar 30;501(1-2):350-61
pubmed: 26844786
Indian Dermatol Online J. 2013 Oct;4(4):267-72
pubmed: 24350003
Molecules. 2016 Dec 15;21(12):
pubmed: 27983701
J Clin Med. 2019 Apr 02;8(4):null
pubmed: 30987008
Allergy Asthma Immunol Res. 2018 May;10(3):207-215
pubmed: 29676067
Paediatr Drugs. 2013 Aug;15(4):303-10
pubmed: 23549982
Lipids Health Dis. 2016 Jan 19;15:13
pubmed: 26786937
Ther Deliv. 2012 Aug;3(8):941-59
pubmed: 22946429
Nat Rev Dis Primers. 2018 Jun 21;4(1):1
pubmed: 29930242
Pharmazie. 2011 Jul;66(7):473-8
pubmed: 21812320
Int J Nanomedicine. 2014 Nov 26;9:5449-60
pubmed: 25473283
Curr Drug Targets. 2015;16(14):1671-81
pubmed: 26601723
Int J Pharm. 2014 Oct 1;473(1-2):591-8
pubmed: 25102113
An Bras Dermatol. 2018 Jan-Feb;93(1):104-107
pubmed: 29641707
Regul Toxicol Pharmacol. 2015 Jul;72(2):310-22
pubmed: 25979643